Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SION-451 Combinations in Healthy Participants
NCT07035990Phase 1Completed
- Sponsor
- Sionna Therapeutics, Inc.
- Start
- Jul 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SION-451 in cystic fibrosis (CF) (4 arms), sponsored by Sionna Therapeutics, Inc. Primary endpoint: Incidence of Treatment Emergent Adverse Events at 21 days. Started Jul 2025; status: completed.
02
Drugs
SION-451
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT07035990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035990.